Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after Stifel Nicolaus initiates coverage with a Buy rating citing "a potentially significant value-creating event … with the pending Enobosarm Phase 3 data." Price target is $7, representing a 40% upside from the stock's current price.
Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs